Strong and Specific Protective and Therapeutic Immunity Induced by Single HLA-A2.1 Restricted Epitope DNA Vaccine in Rabbits

Jiafen Hu; Todd D. Schell; Xuwen Peng; Nancy M. Cladel; Karla K. Balogh; Neil D. Christensen

doi:10.1016/j.provac.2009.07.003

Strong and Specific Protective and Therapeutic Immunity Induced by Single HLA-A2.1 Restricted Epitope DNA Vaccine in Rabbits

Jiafen Hu
, Todd D. Schell
, Xuwen Peng
, Nancy M. Cladel
, Karla K. Balogh
, Neil D. Christensen

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

An HLA-A2.1 transgenic rabbit /Cottontail rabbit papillomavirus (CRPV) infection model has been reported previously. In this study, we incorporated online MHCI epitope prediction software and HLA-A2.1 transgenic mouse and rabbit systems together to demonstrate an efficient way to identify and test immunogenicity of two HLA-A2.1 restricted epitopes from CRPVE1 (161-169 LLFRQAHSV and 303-311 MLQEKPFQL). Both epitopes were able to induce specific cytotoxic CD8 T cells in HLA-A2.1 mice and rabbits after peptide and DNA immunization and in vitro stimulation respectively. Using an epitope DNA vaccination method, we achieved partial and complete protection against CRPV DNA challenge by CRPVE1/161-169 and CRPVE1/303-311 respectively in HLA-A2.1 transgenic outbred rabbits. CRPVE1/303-311 also showed strong and specific therapeutic effects in CRPV-infected HLA-A2.1 transgenic outbred rabbits. Interestingly, epitope CRPVE1/303-311 (but not E1/161-169) showed strong protective immunity in non-transgenic EIII/JC inbred (but not outbred) NZW rabbits. Our data demonstrates an efficient way to identify HLA-A2.1 restricted epitopes for the development of prophylactic and therapeutic vaccines.

Original language	English (US)
Pages (from-to)	4-14
Number of pages	11
Journal	Procedia in Vaccinology
Volume	1
Issue number	1
DOIs	https://doi.org/10.1016/j.provac.2009.07.003
State	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Immunology
Pharmaceutical Science
Drug Discovery
Infectious Diseases

Access to Document

10.1016/j.provac.2009.07.003

Cite this

@article{f6a05463cfff4ef898e8a9b5115edd47,

title = "Strong and Specific Protective and Therapeutic Immunity Induced by Single HLA-A2.1 Restricted Epitope DNA Vaccine in Rabbits",

abstract = "An HLA-A2.1 transgenic rabbit /Cottontail rabbit papillomavirus (CRPV) infection model has been reported previously. In this study, we incorporated online MHCI epitope prediction software and HLA-A2.1 transgenic mouse and rabbit systems together to demonstrate an efficient way to identify and test immunogenicity of two HLA-A2.1 restricted epitopes from CRPVE1 (161-169 LLFRQAHSV and 303-311 MLQEKPFQL). Both epitopes were able to induce specific cytotoxic CD8 T cells in HLA-A2.1 mice and rabbits after peptide and DNA immunization and in vitro stimulation respectively. Using an epitope DNA vaccination method, we achieved partial and complete protection against CRPV DNA challenge by CRPVE1/161-169 and CRPVE1/303-311 respectively in HLA-A2.1 transgenic outbred rabbits. CRPVE1/303-311 also showed strong and specific therapeutic effects in CRPV-infected HLA-A2.1 transgenic outbred rabbits. Interestingly, epitope CRPVE1/303-311 (but not E1/161-169) showed strong protective immunity in non-transgenic EIII/JC inbred (but not outbred) NZW rabbits. Our data demonstrates an efficient way to identify HLA-A2.1 restricted epitopes for the development of prophylactic and therapeutic vaccines.",

author = "Jiafen Hu and Schell, \{Todd D.\} and Xuwen Peng and Cladel, \{Nancy M.\} and Balogh, \{Karla K.\} and Christensen, \{Neil D.\}",

note = "Funding Information: We thank Martin Pickel and Jeremy Haley for excellent help with the animals. This work was supported by the National Cancer Institute grant RO1 CA47622 from the National Institutes of Health and the Jake Gittlen Memorial Golf Tournament. Table 1. Partial and complete protection stimulated by CRPVE1/161-169 and CRPVE1/303-311 epitope DNA vaccination in outbred HLA-A2.1 transgenic rabbits",

year = "2009",

doi = "10.1016/j.provac.2009.07.003",

language = "English (US)",

volume = "1",

pages = "4--14",

journal = "Procedia in Vaccinology",

issn = "1877-282X",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Strong and Specific Protective and Therapeutic Immunity Induced by Single HLA-A2.1 Restricted Epitope DNA Vaccine in Rabbits

AU - Hu, Jiafen

AU - Schell, Todd D.

AU - Peng, Xuwen

AU - Cladel, Nancy M.

AU - Balogh, Karla K.

AU - Christensen, Neil D.

N1 - Funding Information: We thank Martin Pickel and Jeremy Haley for excellent help with the animals. This work was supported by the National Cancer Institute grant RO1 CA47622 from the National Institutes of Health and the Jake Gittlen Memorial Golf Tournament. Table 1. Partial and complete protection stimulated by CRPVE1/161-169 and CRPVE1/303-311 epitope DNA vaccination in outbred HLA-A2.1 transgenic rabbits

PY - 2009

Y1 - 2009

N2 - An HLA-A2.1 transgenic rabbit /Cottontail rabbit papillomavirus (CRPV) infection model has been reported previously. In this study, we incorporated online MHCI epitope prediction software and HLA-A2.1 transgenic mouse and rabbit systems together to demonstrate an efficient way to identify and test immunogenicity of two HLA-A2.1 restricted epitopes from CRPVE1 (161-169 LLFRQAHSV and 303-311 MLQEKPFQL). Both epitopes were able to induce specific cytotoxic CD8 T cells in HLA-A2.1 mice and rabbits after peptide and DNA immunization and in vitro stimulation respectively. Using an epitope DNA vaccination method, we achieved partial and complete protection against CRPV DNA challenge by CRPVE1/161-169 and CRPVE1/303-311 respectively in HLA-A2.1 transgenic outbred rabbits. CRPVE1/303-311 also showed strong and specific therapeutic effects in CRPV-infected HLA-A2.1 transgenic outbred rabbits. Interestingly, epitope CRPVE1/303-311 (but not E1/161-169) showed strong protective immunity in non-transgenic EIII/JC inbred (but not outbred) NZW rabbits. Our data demonstrates an efficient way to identify HLA-A2.1 restricted epitopes for the development of prophylactic and therapeutic vaccines.

AB - An HLA-A2.1 transgenic rabbit /Cottontail rabbit papillomavirus (CRPV) infection model has been reported previously. In this study, we incorporated online MHCI epitope prediction software and HLA-A2.1 transgenic mouse and rabbit systems together to demonstrate an efficient way to identify and test immunogenicity of two HLA-A2.1 restricted epitopes from CRPVE1 (161-169 LLFRQAHSV and 303-311 MLQEKPFQL). Both epitopes were able to induce specific cytotoxic CD8 T cells in HLA-A2.1 mice and rabbits after peptide and DNA immunization and in vitro stimulation respectively. Using an epitope DNA vaccination method, we achieved partial and complete protection against CRPV DNA challenge by CRPVE1/161-169 and CRPVE1/303-311 respectively in HLA-A2.1 transgenic outbred rabbits. CRPVE1/303-311 also showed strong and specific therapeutic effects in CRPV-infected HLA-A2.1 transgenic outbred rabbits. Interestingly, epitope CRPVE1/303-311 (but not E1/161-169) showed strong protective immunity in non-transgenic EIII/JC inbred (but not outbred) NZW rabbits. Our data demonstrates an efficient way to identify HLA-A2.1 restricted epitopes for the development of prophylactic and therapeutic vaccines.

UR - https://www.scopus.com/pages/publications/71549116707

UR - https://www.scopus.com/pages/publications/71549116707#tab=citedBy

U2 - 10.1016/j.provac.2009.07.003

DO - 10.1016/j.provac.2009.07.003

M3 - Article

AN - SCOPUS:71549116707

SN - 1877-282X

VL - 1

SP - 4

EP - 14

JO - Procedia in Vaccinology

JF - Procedia in Vaccinology

IS - 1

ER -

Strong and Specific Protective and Therapeutic Immunity Induced by Single HLA-A2.1 Restricted Epitope DNA Vaccine in Rabbits

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this